Latest news with #GuardianPharmacyServices
Business Wire
02-06-2025
- Business
- Business Wire
Guardian Pharmacy Services Expands Pacific Northwest Footprint with Acquisition of Washington-based Mercury Pharmacy Services
ATLANTA--(BUSINESS WIRE)-- Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's largest and most innovative long-term care (LTC) pharmacy services companies, today announced its acquisition of Mercury Pharmacy Services, a leading LTC pharmacy based in Mountlake Terrace, Wash. This acquisition marks Guardian's first pharmacy location in Washington and represents one of the company's larger recent single-pharmacy deals. With this strategic addition, Guardian expands its footprint into the Pacific Northwest, positioning the company to support the growing demand for LTC pharmacy services across this area. The new location will serve residents in assisted living, skilled nursing, and behavioral health communities, as well as individuals with intellectual and developmental disabilities. With this strategic addition, Guardian Pharmacy Services expands its footprint into the Pacific Northwest, positioning the company to support the growing demand for LTC pharmacy services across this area. Share Founded in 2001, Mercury Pharmacy Services is among the largest providers of LTC pharmacy services in the Seattle-Tacoma area and serves residents and LTC communities across the state of Washington and adjoining areas. All existing leadership and staff at Mercury Pharmacy Services will remain in place, continuing to operate under the same name. 'As we continue our nationwide expansion, we remain focused on identifying outstanding local pharmacies in regions where senior living operators have expressed a clear need for high-quality, LTC pharmacy services,' said Fred Burke, president and CEO of Guardian Pharmacy Services. 'Demand for dependable, responsive LTC pharmacy service has grown significantly across Washington, and our acquisition of Mercury Pharmacy Services allows us to meet that need with a financially strong, high-performing pharmacy already delivering exceptional care.' As with Guardian's other acquisitions, Mercury Pharmacy Services will benefit from the company's unique business model. This enables the local pharmacy teams to focus on customer service and the specialized needs of the communities and residents they serve, while Guardian's centralized Corporate Support Team assists with the many complex behind-the-scenes business functions, including data analytics, HR, IT, payor relations, national sales and more. Founded in 2004, Guardian Pharmacy Services has expanded from a single location to more than 50 pharmacies serving approximately 7,000 LTC facilities across the U.S. This growth has been fueled by a balanced strategy of organic expansion, greenfield startups, and acquisitions, supporting the company's success in a rapidly evolving market. For more information, visit About Guardian Pharmacy Services Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities ('LTCFs') adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. As of March 31, 2025, our 51 pharmacies served approximately 189,000 residents in approximately 7,000 LTCFs across 38 states. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding anticipated growth, future hiring, and expanded service offerings. These statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, including those described in Guardian's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission from time to time, and which are publicly available at and via our website, Actual results may differ materially from those expressed or implied in these statements. Guardian Pharmacy Services undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Business Wire
23-05-2025
- Business
- Business Wire
Guardian Pharmacy Services Announces Pricing of Underwritten Public Offering of Class A Common Stock
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. ('Guardian') (NYSE: GRDN) today announced the pricing of the previously announced underwritten public offering (the 'Offering') of 7,500,000 shares of its Class A common stock, at a public offering price of $21.00 per share, of which 6,059,553 shares will be sold by certain selling stockholders and 1,440,447 shares will be issued and sold by Guardian as part of a non-dilutive 'synthetic secondary' transaction, as described below. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of Class A common stock at the public offering price, less the underwriting discount. The Offering is expected to close on May 27, 2025, subject to customary closing conditions. The Offering is considered non-dilutive as Guardian intends to use all of the net proceeds it receives in the Offering to repurchase from certain stockholders 1,440,447 shares of Class A common stock, at a purchase price per share equal to the public offering price in the Offering, less the underwriting discount (the 'Synthetic Secondary'). Accordingly, Guardian will not retain any proceeds from the Offering and, upon completion of the Offering and the Synthetic Secondary, the total number of outstanding shares of Class A common stock will remain the same. The shares to be repurchased by Guardian consist of shares of Class A common stock that were issued upon conversion of shares of Guardian's Class B common stock that were originally issued in connection with its corporate reorganization in September 2024. The repurchases are expected to be completed not later than May 29, 2025, subject to closing of the Offering. Guardian will not receive any proceeds from the offering of shares by the selling stockholders in the Offering. Raymond James is acting as lead bookrunning manager and as representative of the underwriters for the Offering. Stephens Inc. and Truist Securities are acting as joint bookrunning managers for the Offering. A registration statement on Form S-1 relating to the Offering was declared effective by the U.S. Securities and Exchange Commission ('SEC') today on May 22, 2025. The Offering is being made only by means of a prospectus. Once available, copies of the final prospectus may be obtained from: Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@ This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. About Guardian Pharmacy Services Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities ('LTCFs') adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. As of March 31, 2025, our 51 pharmacies served approximately 189,000 residents in approximately 7,000 LTCFs across 38 states. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are all statements other than those of historical fact. Words such as 'aims,' 'anticipates,' 'believes,' 'contemplates,' 'continues,' 'estimates,' 'expects,' 'intends,' 'may,' 'plans,' 'seeks,' 'should,' 'will,' 'would' and similar expressions are often, but not always, used to identify forward-looking statements. These forward-looking statements include statements regarding the Offering and the Synthetic Secondary, including the expected timing and completion thereof, and Guardian's use of the net proceeds to it from the Offering. These forward-looking statements are based on management's current expectations and beliefs and are inherently subject to risks and uncertainties, including, among others, uncertainties related to market conditions, and those other risks and uncertainties more fully described under 'Risk Factors' in Guardian's Annual Report on Form 10-K for the year ended December 31, 2024 and the registration statement on Form S-1 relating to the Offering. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.
Yahoo
23-05-2025
- Business
- Yahoo
Guardian Pharmacy Services Announces Pricing of Underwritten Public Offering of Class A Common Stock
ATLANTA, May 23, 2025--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. ("Guardian") (NYSE: GRDN) today announced the pricing of the previously announced underwritten public offering (the "Offering") of 7,500,000 shares of its Class A common stock, at a public offering price of $21.00 per share, of which 6,059,553 shares will be sold by certain selling stockholders and 1,440,447 shares will be issued and sold by Guardian as part of a non-dilutive "synthetic secondary" transaction, as described below. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of Class A common stock at the public offering price, less the underwriting discount. The Offering is expected to close on May 27, 2025, subject to customary closing conditions. The Offering is considered non-dilutive as Guardian intends to use all of the net proceeds it receives in the Offering to repurchase from certain stockholders 1,440,447 shares of Class A common stock, at a purchase price per share equal to the public offering price in the Offering, less the underwriting discount (the "Synthetic Secondary"). Accordingly, Guardian will not retain any proceeds from the Offering and, upon completion of the Offering and the Synthetic Secondary, the total number of outstanding shares of Class A common stock will remain the same. The shares to be repurchased by Guardian consist of shares of Class A common stock that were issued upon conversion of shares of Guardian's Class B common stock that were originally issued in connection with its corporate reorganization in September 2024. The repurchases are expected to be completed not later than May 29, 2025, subject to closing of the Offering. Guardian will not receive any proceeds from the offering of shares by the selling stockholders in the Offering. Raymond James is acting as lead bookrunning manager and as representative of the underwriters for the Offering. Stephens Inc. and Truist Securities are acting as joint bookrunning managers for the Offering. A registration statement on Form S-1 relating to the Offering was declared effective by the U.S. Securities and Exchange Commission ("SEC") today on May 22, 2025. The Offering is being made only by means of a prospectus. Once available, copies of the final prospectus may be obtained from: Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@ This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. About Guardian Pharmacy Services Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities ("LTCFs") adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. As of March 31, 2025, our 51 pharmacies served approximately 189,000 residents in approximately 7,000 LTCFs across 38 states. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are all statements other than those of historical fact. Words such as "aims," "anticipates," "believes," "contemplates," "continues," "estimates," "expects," "intends," "may," "plans," "seeks," "should," "will," "would" and similar expressions are often, but not always, used to identify forward-looking statements. These forward-looking statements include statements regarding the Offering and the Synthetic Secondary, including the expected timing and completion thereof, and Guardian's use of the net proceeds to it from the Offering. These forward-looking statements are based on management's current expectations and beliefs and are inherently subject to risks and uncertainties, including, among others, uncertainties related to market conditions, and those other risks and uncertainties more fully described under "Risk Factors" in Guardian's Annual Report on Form 10-K for the year ended December 31, 2024 and the registration statement on Form S-1 relating to the Offering. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise. View source version on Contacts Ashley Ragsdale StocktonSenior Director, Investor RelationsGuardian Pharmacy Services, Inc.470-995-1798IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20-05-2025
- Business
- Business Wire
Guardian Pharmacy Services Announces Launch of Underwritten Public Offering of Class A Common Stock
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. ('Guardian') (NYSE: GRDN) today announced the launch of a proposed underwritten public offering (the 'Offering') of 7,500,000 shares of its Class A common stock, consisting of 6,059,553 shares being offered by certain selling stockholders and 1,440,447 newly issued shares being offered by Guardian as part of a non-dilutive 'synthetic secondary' transaction, as described below. In addition, the selling stockholders intend to grant the underwriters a 30‑day option to purchase up to an additional 1,125,000 shares of Class A common stock at the public offering price, less the underwriting discount. The proposed Offering is considered non-dilutive as Guardian intends to use all of the net proceeds it receives in the Offering to repurchase from certain stockholders a number of shares of Class A common stock equal to the number of shares being issued and sold by Guardian in the Offering, at a purchase price per share equal to the public offering price in the Offering, less the underwriting discount (the 'Synthetic Secondary'). Accordingly, Guardian will not retain any proceeds from the Offering and, upon completion of the Offering and the Synthetic Secondary, the total number of outstanding shares of Class A common stock will remain the same. The shares to be repurchased by Guardian consist of shares of Class A common stock that were issued upon conversion of shares of Guardian's Class B common stock that were originally issued in connection with its corporate reorganization in September 2024. Guardian will not receive any proceeds from the offering of shares by the selling stockholders in the Offering. Raymond James is acting as lead bookrunning manager of the offering and as representative of the underwriters for the proposed Offering. Stephens Inc. and Truist Securities are acting as joint bookrunning managers for the offering. A registration statement on Form S-1 relating to the proposed Offering has been filed with the U.S. Securities and Exchange Commission ('SEC') but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. The proposed Offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering can be obtained from: Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@ About Guardian Pharmacy Services Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities ('LTCFs') adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. As of March 31, 2025, our 51 pharmacies served approximately 189,000 residents in approximately 7,000 LTCFs across 38 states. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are all statements other than those of historical fact. Words such as 'aims,' 'anticipates,' 'believes,' 'contemplates,' 'continues,' 'estimates,' 'expects,' 'intends,' 'may,' 'plans,' 'seeks,' 'should,' 'will,' 'would' and similar expressions are often, but not always, used to identify forward-looking statements. These forward-looking statements include statements regarding the proposed Offering and the Synthetic Secondary, and Guardian's use of the net proceeds to it from the proposed Offering. These forward-looking statements are based on management's current expectations and beliefs and are inherently subject to risks and uncertainties, including, among others, uncertainties related to market conditions, and those other risks and uncertainties more fully described under 'Risk Factors' in Guardian's Annual Report on Form 10-K for the year ended December 31, 2024 and the registration statement on Form S-1 relating to the proposed Offering. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.
Yahoo
20-05-2025
- Business
- Yahoo
Guardian Pharmacy Services Announces Launch of Underwritten Public Offering of Class A Common Stock
ATLANTA, May 20, 2025--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. ("Guardian") (NYSE: GRDN) today announced the launch of a proposed underwritten public offering (the "Offering") of 7,500,000 shares of its Class A common stock, consisting of 6,059,553 shares being offered by certain selling stockholders and 1,440,447 newly issued shares being offered by Guardian as part of a non-dilutive "synthetic secondary" transaction, as described below. In addition, the selling stockholders intend to grant the underwriters a 30‑day option to purchase up to an additional 1,125,000 shares of Class A common stock at the public offering price, less the underwriting discount. The proposed Offering is considered non-dilutive as Guardian intends to use all of the net proceeds it receives in the Offering to repurchase from certain stockholders a number of shares of Class A common stock equal to the number of shares being issued and sold by Guardian in the Offering, at a purchase price per share equal to the public offering price in the Offering, less the underwriting discount (the "Synthetic Secondary"). Accordingly, Guardian will not retain any proceeds from the Offering and, upon completion of the Offering and the Synthetic Secondary, the total number of outstanding shares of Class A common stock will remain the same. The shares to be repurchased by Guardian consist of shares of Class A common stock that were issued upon conversion of shares of Guardian's Class B common stock that were originally issued in connection with its corporate reorganization in September 2024. Guardian will not receive any proceeds from the offering of shares by the selling stockholders in the Offering. Raymond James is acting as lead bookrunning manager of the offering and as representative of the underwriters for the proposed Offering. Stephens Inc. and Truist Securities are acting as joint bookrunning managers for the offering. A registration statement on Form S-1 relating to the proposed Offering has been filed with the U.S. Securities and Exchange Commission ("SEC") but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. The proposed Offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering can be obtained from: Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@ About Guardian Pharmacy Services Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities ("LTCFs") adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. As of March 31, 2025, our 51 pharmacies served approximately 189,000 residents in approximately 7,000 LTCFs across 38 states. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are all statements other than those of historical fact. Words such as "aims," "anticipates," "believes," "contemplates," "continues," "estimates," "expects," "intends," "may," "plans," "seeks," "should," "will," "would" and similar expressions are often, but not always, used to identify forward-looking statements. These forward-looking statements include statements regarding the proposed Offering and the Synthetic Secondary, and Guardian's use of the net proceeds to it from the proposed Offering. These forward-looking statements are based on management's current expectations and beliefs and are inherently subject to risks and uncertainties, including, among others, uncertainties related to market conditions, and those other risks and uncertainties more fully described under "Risk Factors" in Guardian's Annual Report on Form 10-K for the year ended December 31, 2024 and the registration statement on Form S-1 relating to the proposed Offering. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise. View source version on Contacts Ashley Ragsdale StocktonSenior Director, Investor RelationsGuardian Pharmacy Services, Inc.470-995-1798IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
